Advertisement
Skip to Content

Catalent Inc CTLT Stock Quote

| Rating as of

NYSE: CTLT

Last close prices updated as of Feb 03, 2023, 7:00 PM EST | USD | BATS BZX Real-Time Price
  • Last Close 56.05
  • Sector Healthcare
  • Industry Drug Manufacturers - Specialty & Generic
  • Investment Style Mid Blend
  • Day Range 55.06  –  57.52
  • Year Range 40.69  –  115.34
  • Market Cap 10.0870 Bil
  • Volume / Avg 3.0 Mil /  3.1 Mil
  • Price / Sales 2.09
  • Price / Book 2.15
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis CTLT

Valuation
Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Narrow-Moat Catalent Faces Macro Headwinds, but We Maintain Long-Term Positive Outlook

Rachel Elfman Equity Analyst

Business Strategy and Outlook

| Rachel Elfman |

Catalent is a leading contract development and manufacturing organization, or CDMO. The company has an extensive network of partnerships with pharmaceutical and biotechnology firms that leverage its expertise and scale to optimize drug production and avoid the risks of in-house drug manufacturing. The challenges and compliance risks associated with changing a drug’s manufacturing process create a sticky relationship for Catalent’s customers. Drug companies tend to stick with trusted suppliers with good track records of regulatory compliance, which makes them unlikely to switch to a different CDMO.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics CTLT

Company Profile CTLT

Business Description

Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.

Contact
14 Schoolhouse Road
Somerset, NJ, 08873
Industry Drug Manufacturers - Specialty & Generic
Employees 19,000

Related Articles CTLT

FAQs for Catalent Inc Stock

No. CTLT does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

CTLT’s market cap is 10.09 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

CTLT’s stock style is Mid Core.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

CTLT’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare CTLT’s historical performance against its industry peers and the overall market.